SHEET A-06 / QUERY SCHEDULE
BPC-157 TB-500 FAQ: Twenty Questions, Answered from the Record
Definitional, mechanistic, efficacy, safety, and regulatory questions about the Wolverine blend — each answered directly and cited to the literature or the FDA record.
Definitional
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to residues 17-23 of Thymosin Beta-4 [3]. The Wolverine blend pairs the two. Neither is an FDA-approved drug.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair stack. It is not a single chemical entity or an approved product, and no standardized composition or ratio is clinically validated. Most TB-500 efficacy data come from full-length Thymosin Beta-4 [4].
What is the BPC-157 and TB-500 blend used for in research?
In animal models the two constituents are studied separately for tissue repair: BPC-157 for tendon, ligament, and muscle healing [1]; TB-500 / Thymosin Beta-4 for cell migration, wound re-epithelialization, and angiogenesis [4]. The combination itself has no controlled study [8].
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid pentadecapeptide (~1419.5 Da) from a human gastric-juice protein, acting on VEGFR2/eNOS angiogenic and growth-hormone-receptor pathways [2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889 Da) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration [3].
Mechanism
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) [2] while TB-500 supplies an intracellular actin-sequestration signal driving cell migration [3]. The synergy is a theoretical extrapolation from two non-overlapping mechanisms, not a finding from a controlled combination study [8].
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
In research models, yes — by distinct routes. BPC-157 up-regulates VEGFR2 and promotes its internalization, with downstream VEGFR2-Akt-eNOS signaling, increasing vessel density and speeding blood-flow recovery in ischemic muscle [2]. Thymosin Beta-4 promotes angiogenesis via endothelial migration, including restoring angiogenesis in aged animals [6].
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1. X-ray crystallography of a gelsolin-domain-1-Thymosin-Beta-4 hybrid bound to actin established that Thymosin Beta-4 sequesters the actin monomer by capping both ends, preventing polymerization [3] — the cytoskeletal basis for its cell-migration role.
How does BPC-157 work compared to TB-500?
They act through largely non-overlapping pathways. BPC-157 is a local cytoprotective and pro-angiogenic signal (VEGFR2 up-regulation, then Akt, then eNOS) [2] while TB-500 is an intracellular actin-sequestration signal (G-actin binding via LKKTETQ) regulating cytoskeletal dynamics and migration [3].
Evidence and efficacy
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 (36 studies, only 1 human) makes no mention of TB-500 or combination use; the synergy claim is an extrapolation [8].
Are there human clinical trials on the BPC-157 + TB-500 combination?
No. There are no controlled clinical trials of the combination. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies [10], and TB-500 human data are for full-length Thymosin Beta-4, not the heptapeptide. Recent reviews call BPC-157 investigational [10].
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
The evidence is animal-model and single-compound. BPC-157 accelerated healing of a transected rat Achilles tendon across biomechanical, functional, and microscopic measures, and stimulated tendocyte growth in vitro [1]; Thymosin Beta-4 enhanced ligament healing in animal models [4]. No human or combination tendon trial exists [8].
Does BPC-157 and TB-500 help muscle tears and recovery?
Only in animal models, separately. BPC-157's tendon and tendocyte data [1] and Thymosin Beta-4's migration and cell-mobilization activity [4] are the basis of the recovery rationale. Human combination recovery data do not exist [9].
Does the BPC-157 TB-500 blend help wound healing?
In animal models, the TB-500 side has wound-healing support: Thymosin Beta-4 promoted angiogenesis, wound healing, and hair-follicle development in normal and aged rodents [6], and the consolidated review describes re-epithelialization and reduced scar-forming myofibroblasts [4]. These are single-compound animal findings.
How long does it take BPC-157 and TB-500 to work for an injury?
No human timeline exists for the blend. The underlying evidence is animal-model: BPC-157 accelerated tendon healing across multiple measures in rats [1], but rodent recovery timelines do not translate to validated human expectations, and recent reviews treat both constituents as investigational [10].
Safety and regulatory
Is TB-500 bad for your heart?
There is no human cardiac-safety data for the TB-500 heptapeptide. BPC-157 has been reported to modulate vasomotor tone via the Src-Caveolin-1-eNOS pathway in animal and endothelial models [5], and 2025-2026 reviews stress that human safety data for both constituents are scarce and that both remain investigational [9] [10].
What are the side effects of BPC-157 and TB-500?
There is no controlled human safety dataset for the blend. A 2025 BPC-157 systematic review explicitly found no clinical safety data [8]; 2025-2026 reviews note that unapproved musculoskeletal peptides can carry potential for serious harm and operate largely outside regulatory oversight [9]. Long-term human safety of the combination is unknown.
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use, and the blend has no approved indication [12]. Both are prohibited by WADA — BPC-157 under the S0 non-approved-substances category; TB-500 / Thymosin Beta-4 under prohibited peptide and tissue-repair categories. In 2023, FDA placed both in its 503A Category 2 of bulk substances flagged for significant safety risks [11].
Is Wolverine legal?
Status depends on jurisdiction and context. Neither constituent is an FDA-approved medicine, and both are WADA-prohibited in sport. In the U.S. compounding framework, both are currently 503A Category 2 bulk substances, restricting pharmacy compounding access while that status stands [11] [12]. See the Wolverine legal status and 503A compounding page.
Can you get BPC-157 from a compounding pharmacy?
Under current FDA status, routine 503A pharmacy compounding of BPC-157 is restricted: FDA placed it in Category 2, outside the enforcement-discretion policy, effective with the September 29, 2023 list update [11]. BPC-157 is on the PCAC agenda for July 23-24, 2026 as a bulks-list candidate, but that is a scheduled discussion, not a change in current status [13].
What is the FDA 503A status of Wolverine?
Both components of the Wolverine blend are in FDA's 503A Category 2. FDA placed BPC-157, and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," on its list of bulk substances that may present significant safety risks, effective with the September 29, 2023 update [11]. Neither component nor the blend is an FDA-approved medicine [12].